A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery-the first predictive biomarker in this setting.

In the first prospective, randomized trial to validate a predictive gene expression test for hormone therapy in prostate cancer, patients with a prostate tumor subtype known as luminal B had much lower risks of recurrence and metastasis when radiation was complemented by apalutamide, a type of hormone therapy. Patients without this tumor subtype, however, saw no improvement. Results of the phase II BALANCE trial (NRG Oncology GU006) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

“We’ve been searc

See Full Page